Sex Differences in Immunology: More Severe Development of Experimental Pulmonary Hypertension in Male Rats Exposed to Vascular Endothelial Growth Factor Receptor Blockade

Table 1

Right heart hemodynamics at 4 weeks.

Group; ()	RNU_M; (8)	RNU_F; (8)	SU_M; (8)	SU_F; (11)
Semaxanib (mg/kg)	0	0	40	40
Heart rate (beat/min)	269 ± 37	311 ± 35	296 ± 48	280 ± 73
RVESP (mm Hg)	21 ± 2.5	24.3 ± 8.1	66.3 ± 8.9	29.5 ± 13.4
RVEDP (mm Hg)	1.5 ± 3.5	3 ± 3.6	6.2 ± 2.8^§	2.1 ± 4.3
CO (mL/min)	134 ± 4	122 ± 5	58 ± 24	89 ± 17
PVR (dyn⋅s⋅cm^−5)	0.013 ± 0.002	0.016 ± 0.006	0.103 ± 0.06	0.027 ± 0.01
max (mm Hg/s)	1173 ± 161	1311 ± 414	2636 ± 495	1374 ± 320
min (mm Hg/s)	−1318 ± 37	−871 ± 232	−2370 ± 912	−1072 ± 415
(mm Hg/µL)	0.19 ± 0.05	0.21 ± 0.15	0.12 ± 0.06	0.18 ± 0.05
(mm Hg/µL)	0.04 ± 0.01	0.06 ± 0.03	0.33 ± 0.12	0.09 ± 0.02
	4.75 ± 0.63	3.5 ± 0.45	0.36 ± 0.17	2.1 ± 0.34

RVESP: right ventricular end-systolic pressure; RVEDP: right ventricular end-diastolic pressure; CO: cardiac output; PVR: pulmonary vascular resistance; max: right ventricular maximal isovolumic rate of development of ventricular pressure; min: right ventricular minimal isovolumic rate of development of ventricular pressure. Other abbreviations are in text. explains for comparison with SU_F; # explains for comparison with RNU_M; explains for comparison with RNU_F.